Select publication to see the relevant sections.

Publication Date

    E.g., 2018-03-22
    E.g., 2018-03-22

Archive Search

255160 items
1:32 PM, Mar 22, 2018  |  BioCentury | Finance

NMD treats A to Z

The broad applicability of NMD Pharma ApS’s approach to treating neuromuscular conditions persuaded INKEF Capital to lead the company’s tranched €38 million ($46.6 million) series A round. Fellow new investor Roche Venture Fund and existing...
12:22 PM, Mar 22, 2018  |  BC Extra | Company News

AstraZeneca hyperkalemia therapy gets EU approval

AstraZeneca plc (LSE:AZN; NYSE:AZN) said the European Commission approved its MAA for Lokelma sodium zirconium cyclosilicate (ZS-9) to treat hyperkalemia in adults. An AZ spokesperson told BioCentury the pharma expects to launch Lokelma this year,...
11:40 AM, Mar 22, 2018  |  BC Extra | Financial News

Tempus reaps $80M in series D round

Tempus Labs Inc. (Chicago, Ill.) raised $80 million in a series D round from existing investors New Enterprise Associates and Revolution Growth, as well as new investors Kinship Trust and funds advised by T. Rowe...
10:39 AM, Mar 22, 2018  |  BC Extra | Politics & Policy

Right-to-try bill clears House, heads to Senate

The House of Representatives passed a right-to-try bill late Wednesday that seeks to authorize using investigational treatments for terminally ill patients. The House voted 267-149 to pass the bill, titled the Trickett Wendler, Frank Mongiello, Jordan...
9:58 AM, Mar 22, 2018  |  BC Innovations | Distillery Therapeutics


INDICATION: Colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting RIPK1 or MCU could help treat colorectal cancer. In patient samples, tumor levels of RIPK1 and MCU were higher than in adjacent normal...
9:58 AM, Mar 22, 2018  |  BC Innovations | Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes Patient sample and yeast studies suggest promoting ZMPSTE24 expression could help treat Type II diabetes. Whole-exome sequencing of patients and healthy volunteers identified associations between loss-of-function mutations in ZMPSTE24 and the disease. In a...
9:58 AM, Mar 22, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Escherichia Cell culture studies suggest an antimicrobial peptide inhibitor of the bacterial ribosomal 50S subunit could help treat E. coli infection. An in silico screen of the genome of the bottlenose dolphin Tursiops truncatus for...
9:58 AM, Mar 22, 2018  |  BC Innovations | Distillery Therapeutics


INDICATION: Cognitive dysfunction Mouse studies suggest inhibiting ABLIM3 could help treat age-related cognitive dysfunction. In a mouse model of the disease, intrahippocampal injection of ABLIM3-targeting shRNA increased contextual fear memory precision for up to 16 days,...
9:22 AM, Mar 22, 2018  |  BC Extra | Financial News

Arena raises $352.8M after Phase II readout

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) raised $352.8 million through the sale of 8.5 million shares at $41.50 in an upsized follow-on underwritten by Citigroup, Leerink Partners, Cantor Fitzgerald, Credit Suisse, RBC Capital Markets, Guggenheim Securities and...
4:00 AM, Mar 22, 2018  |  BC Extra | Financial News

Third Rock launches immuno-metabolism company Rheos

Immuno-metabolism company Rheos Medicines Inc. (Cambridge, Mass.) emerged from stealth mode with a $60 million series A round from Third Rock Ventures. Rheos aims to discover and develop therapies targeting CD4+ T cells to treat inflammatory...